1350653-23-4

Basic information

• Product Name: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-
• Synonyms: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-;5-fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine;5-fluoro-3-iodo-2H-pyrazolo[3,4-b]pyridine
• CAS NO: 1350653-23-4
• Molecular Formula: C₆H₃FIN₃
• Molecular Weight: 263.0109932
• Mol File: 1350653-23-4.mol

Chemical Properties

• Boiling Point: 382.7±37.0 °C(Predicted)
• Appearance: /
• Density: 2.294±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 6.86±0.40(Predicted)
• CAS DataBase Reference: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-(1350653-23-4)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-(1350653-23-4)

Safety Data

• Hazardous Substances Data: 1350653-23-4(Hazardous Substances Data)

Usage

Uses

1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodois used as a research chemical for the development and synthesis of new compounds in the field of organic chemistry. Its unique structure and functional groups make it a valuable candidate for exploring novel chemical reactions and potential applications in various industries.
Used in Chemical Research Industry:
1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodois used as a research compound for investigating its chemical properties and potential applications in the synthesis of new materials and pharmaceuticals. Its complex structure and functional groups provide a platform for studying the effects of heteroatoms on chemical reactivity and the development of innovative synthetic pathways.
Used in Pharmaceutical Development:
1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodois used as a starting material or intermediate in the synthesis of potential drug candidates. Its heterocyclic nature and functional groups may contribute to the development of new therapeutic agents with unique pharmacological properties, such as novel anticancer, antiviral, or antibacterial agents.
Used in Material Science:
1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodois used as a component in the development of new materials with specific properties, such as electronic, optical, or catalytic applications. Its heterocyclic structure and functional groups may play a role in the design of advanced materials with tailored characteristics for use in various technological applications.

Upstream product

• 870063-52-8 2-chloro-3-hydroxymethyl-5-fluoropyridine 
• 38186-88-8 2-chloro-5-fluoronicotinic acid 
• 1034667-22-5 5-fluoro-1H-pyrazolo[3,4-b]pyridine-3-amine 
• 791644-48-9 2-chloro-5-fluoronicotinonitrile 
• 75302-64-6 2-chloro-5-fluoropyridine-3-carboxamide 
• 82671-02-1 2,6-dichloro-5-fluoro-pyridine-3-carbonitrile 
• 113237-20-0 2,6-dichloro-5-fluoropyridine-3-carboxamide 

Downstream Products

• 1350653-24-5 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 1350653-25-6 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-nitropyrimidine-4,6-diamine 
• 1350653-26-7 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile 
• 1350653-29-0 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-[(E)-phenyldiazenyl]pyrimidine-4,6-diamine 
• 1350653-30-3 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine 
• 1350653-20-1 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yl}carbamate 
• 1350653-21-2 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate 
• 1350653-22-3 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate 
• 1383446-11-4 5-fluoro-3-(4,4,5,5-tetramethyl-1.3.2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3.4-b] pyridine 
• 1383446-18-1 N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 
• 1383446-73-8 N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 
• 1383447-77-5 C₄₀H₃₈F₂N₈O₂ 
• 1383446-78-3 N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)morpholine-4-carboxamide 
• 1383446-80-7 (R)-3-fluoro-N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 

Relevant articles and documents

Preparation method of 5-fluoro-3-iodo-1H-pyrazolo [3, 4-b] pyridine

The invention discloses a preparation method of 5-fluoro-3-iodo-1H-pyrazolo [3, 4-b] pyridine, and belongs to the field of medicinal chemistry. The method specifically comprises the following steps: S1, carrying out reduction reaction on 2-chloro-5-fluoronicotinic acid serving as a starting point to obtain 2-chloro-3-hydroxymethyl-5-fluoropyridine; S2,carrying out oxidation reaction on the 2-chloro-3-hydroxymethyl-5-fluoropyridineto obtain 2-chloro-3-formyl-5-fluoropyridine; S3, enabling that the 2-chloro-3-formyl-5-fluoropyridine is subjected to ring closing through hydrazine hydrate, so that 5-fluoro-1H-pyrazolo [3, 4-b] pyridine is obtained; and S4, carrying out an iodination reaction on the 5-fluoro-1H-pyrazolo [3, 4-b] pyridine, so as to obtain the 5-fluoro-3-iodo-1H-pyrazolo [3, 4-b] pyridine. The four-step reaction of the preparation method does not use strongly corrosive acidic materials, so that the preparation method has the advantages of high safety operability, small damage to equipment and facilities, high safety operability in material storage, transfer and use links, avoidance of diazonium salt reaction for releasing nitrogen in the prior art, high safety controllability, mild reaction conditions, higher safety, simplicity in operation, high yield, and suitability for industrial production.

Pyrazolopyridine compound and use thereof

The present invention relates to a pyrazolopyridine compound and use thereof, and further relates to a pharmaceutical composition comprising the pyrazolopyridine compound. The pyrazolopyridine compound or the pharmaceutical composition can be used as a so

BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT， AMELIORATION OR PREVENTION OF INFLUENZA

The present invention relates to a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing influenza.

PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza

JNJ-63623872 (2) is a first-in-class, orally bioavailable compound that offers significant potential for the treatment of pandemic and seasonal influenza. Early lead optimization efforts in our 7-azaindole series focused on 1,3-diaminocyclohexyl amide and urea substitutions on the pyrimidine-7-azaindole motif. In this work, we explored two strategies to eliminate observed aldehyde oxidase (AO)-mediated metabolism at the 2-position of these 7-azaindole analogues. Substitution at the 2-position of the azaindole ring generated somewhat less potent analogues, but reduced AO-mediated metabolism. Incorporation of a ring nitrogen generated 7-azaindazole analogues that were equipotent to the parent 2-H-7-azaindole, but surprisingly, did not appear to improve AO-mediated metabolism. Overall, we identified multiple 2-substituted 7-azaindole analogues with enhanced AO stability and we present data for one such compound (12) that demonstrate a favorable oral pharmacokinetic profile in rodents. These analogues have the potential to be further developed as anti-influenza agents for the treatment of influenza.

HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS

The present application relates to novel heteroaryl-substituted pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for t

FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF

The present application relates to novel fluoroalkyl-substituted pyrazolopyridines, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

BICYCLIC AZA HETEROCYCLES, AND USE THEREOF

The present application relates to novel bicyclic azaheterocycles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF

The present application relates to novel substituted fused pyrimidines and triazines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES

The present application relates to novel fused pyrimidines and triazines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.